X

Trial Profile

A Phase II Trial of Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Mar 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Lung cancer; Non-small cell lung cancer; Renal cell carcinoma
Focus Therapeutic Use

Most Recent Events

06 Mar 2023 Interventional study model changed from single group assignment to parallel assignment. Allocation changed to non-randomized. Number of arms changed from 1 to 2. Experimental: Cohort 2: Intrapleural Nivolumab in patients with non-small cell lung cancer added to study protocol.
06 Mar 2023 Status changed from recruiting to completed.
16 Feb 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com